Recursion Pharmaceuticals (RXRX) PT Lowered to $6 at BofA Securities
Tweet Send to a Friend
BofA Securities analyst Derik de Bruin lowered the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $6.00 (from $7.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
